Navigation Links
Two-Year Follow-Up Data Show Outstanding Clinical Outcomes and Safety for OrbusNeich's Genous™ Stent in Patients at High Risk for Restenosis
Date:8/16/2011

HONG KONG, Aug. 16, 2011 /PRNewswire/ -- OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.  The two-year follow-up data from the prospective, randomized TRIAS pilot study were published in Catheterization and Cardiovascular Interventions.

No cases of stent thrombosis (ST) were observed in patients treated with the Genous Stent at two years, compared to five cases of ST observed in four patients treated with Taxus. The cumulative rate of cardiac death or myocardial infarction (MI) was 4.1 percent in the Genous group compared to 6.3 percent in the Taxus group.

"It is noteworthy that we did not see any stent thrombosis in patients with complex lesions treated with the Genous Stent," said Marcel Beijk, M.D., of the Academic Medical Center, Amsterdam, and lead author of the paper. "We also saw that the Genous Stent tended to have fewer episodes of target lesion revascularization between one and two years."

The single-center study investigated 193 patients of which 98 received a Genous Stent and 95 received a Taxus stent. Dual antiplatelet therapy was prescribed for at least one month after Genous Stent implantation and for at least six months after Taxus stent implantation.

"For patients with a high risk of restenosis who cannot tolerate the long-term dual antiplatelet therapy normally associated with DES, it is clear that the Genous Stent is an excellent alternative," added Prof. Robbert de Winter, M.D., Ph.D., also of the Academic Medical Center, Amsterdam, and an author of the paper.

The study's primary endpoint was TVF and secondary endpoints included non-cardiac death, target lesion revascularization (TLR), non-TVR and ST at two-year follow-up. TVF was defined as the composite of cardiac death, myocardial infarction and target vessel revascularization (TVR). High risk of restenosis was defined if one of the following applied: a chronic total occlusion, a stenosis with a length of greater than or equal to 23 mm, a lesion in a coronary artery with a diameter less than or equal to 2.8 mm by visual estimation or any lesion in a diabetic patient.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.  

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube  Channel: http://www.youtube.com/user/OrbusNeichMedical.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
2. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
3. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
4. Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
5. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
6. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
7. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
8. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
9. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):